Zydus Cadila on Friday announced that it has received restricted emergency use approval from the Drug Controller General of India (DCGI) to use antiviral drug Virafin for the treatment of moderate COVID-19 infections . A single dose subcutaneous regimen of the antiviral drug will make treatment of COVID-19 disease more convenient. In its regulatory filing, the company said, "When administered early on during COVID, Virafin will help patients recover faster and avoid much of the complications. The country recorded a single day rise of 3,32,730 new cases, the data updated at 8 am showed. It is followed by Uttar Pradesh with 34,254 fresh infections, while Kerala reported 26,995 new cases, the ministry said.

Source: Mint April 23, 2021 09:29 UTC